CTOs on the Move

Fox Chase

www.foxchase.org

 
At Fox Chase Cancer Center, defeating cancer is our calling. Fox Chase is one of the nation`s first dedicated cancer hospitals, and our researchers and physicians have made major contributions to scientific advancement since our establishment more than a century ago in 1904. Fox Chase scientists have made breakthroughs in cancer prevention, diagnosis, treatment, and survivorship, and have earned the highest awards in their fields, including two Nobel Prizes. We translate these pioneering discoveries into world-class clinical care every day - with a single purpose: to defeat cancer and help the people it impacts. This calling is rooted in our ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.foxchase.org
  • 333 Cottman Avenue
    Philadelphia, PA USA 19111
  • Phone: 888.369.2427

Executives

Name Title Contact Details

Similar Companies

South Bend Clinic L L C

South Bend Clinic L L C is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. South Bend Clinic L L C is based in South Bend, IN. You can find more information on South Bend Clinic L L C at www.southbendclinic.com

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

CirrusMD

CirrusMD is the nation`s leading Virtual Care Platform that empowers efficient and more meaningful connections between patients and their healthcare providers.

Pharmatek Laboratories Inc

Pharmatek Laboratories Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Pharmatek Laboratories Inc is based in San Diego, CA. You can find more information on Pharmatek Laboratories Inc at www.pharmatek.com

San Diego Home Health Care

San Diego Home Health Care is a Encinitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.